Format

Send to

Choose Destination
J Infect Dis. 2003 Apr 1;187(7):1157-62. Epub 2003 Mar 19.

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

Author information

1
Merck Research Laboratories, West Point, PA 19486, USA.

Abstract

A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen. Genotyping from 29 nelfinavir failures revealed D30N in 17 (59%) and L90M in 11 (38%) cases. Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus.

PMID:
12660932
DOI:
10.1086/368287
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center